Initial work relied on use of selective anti-catalytic antibodies [24], [39], [40], [41], [42], [43], [44] and more recently PI3K-selective small molecule inhibitors [45], [46], [47], [48], [49], [50], [51], [52], RNAi [53], [54], [55], PI3K KO mice, and cell lines derived from them [56], [57], [58], [59], [60], [61], [62], [63], [64], [65], [66], [67] and analysis of human cancers [35], [68]. The gene discussed is PIK3CD; the disease is cancer.